The Archive · 3 posts
Pioneering allergy solutions! 🌿 Allergy Therapeutics (AGY) leads the charge in allergy treatment innovation on the LSE. 💊 Discover more today!
Allergy Therapeutics expects annual revenue of £59.9 million as Grassmuno supports faster second-half growth and an upbeat FY2027 outlook.
Showing 2 of 3 posts
Allergy Therapeutics reports 7% H1 revenue growth and launches first new German immunotherapy in 20 years, Grassmuno.
JoshuaJanuary 19, 2026
Steady FY2025 results mask Allergy Therapeutics' explosive potential: German Grass MATA MPL approval & VLP Peanut data set to redefine allergy markets in 2025. (136 chars)
JoshuaJuly 21, 2025
July 29, 2026